Navigating HR+ HER2- Early Breast Cancer: A Clinician's Guide to Staging, Work-up, and Risk Stratification

The management of hormone receptor-positive (HR+), HER2-negative (HER2-) early breast cancer is a rapidly evolving field. With an increasing emphasis on personalized medicine, clinicians face the challenge of integrating a vast amount of information to make optimal treatment decisions for their patients. This article provides a comprehensive guide to the staging, work-up, and risk stratification of HR+ HER2- early breast cancer, incorporating the latest clinical practice guidelines and expert insights to enhance clinical decision-making.